The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Determining the rate of tumor growth and decay in patients with metastatic breast cancer as an early efficacy endpoint: A study assessing ixabepilone efficacy.
L. Amiri-Kordestani
No relevant relationships to disclose
I. Jawed
No relevant relationships to disclose
J. Wilkerson
No relevant relationships to disclose
W. D. Stein
No relevant relationships to disclose
S. E. Bates
No relevant relationships to disclose
S. M. Swain
No relevant relationships to disclose
A. T. Fojo
No relevant relationships to disclose